Mcdaniel Terry & Co. Buys 1,000 Shares of Eli Lilly and Company (NYSE:LLY)

Mcdaniel Terry & Co. grew its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 125.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,795 shares of the company's stock after acquiring an additional 1,000 shares during the quarter. Mcdaniel Terry & Co.'s holdings in Eli Lilly and Company were worth $1,386,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of the stock. WealthBridge Capital Management LLC increased its position in shares of Eli Lilly and Company by 5.1% during the fourth quarter. WealthBridge Capital Management LLC now owns 5,516 shares of the company's stock valued at $4,258,000 after acquiring an additional 267 shares in the last quarter. Wealth Alliance boosted its stake in Eli Lilly and Company by 6.6% during the 4th quarter. Wealth Alliance now owns 7,331 shares of the company's stock valued at $5,660,000 after purchasing an additional 457 shares during the last quarter. Sunpointe LLC increased its holdings in shares of Eli Lilly and Company by 12.5% in the 4th quarter. Sunpointe LLC now owns 1,130 shares of the company's stock worth $872,000 after purchasing an additional 126 shares in the last quarter. Cumberland Partners Ltd raised its stake in shares of Eli Lilly and Company by 5.9% in the fourth quarter. Cumberland Partners Ltd now owns 23,273 shares of the company's stock worth $17,967,000 after purchasing an additional 1,289 shares during the last quarter. Finally, Abacus Planning Group Inc. lifted its holdings in shares of Eli Lilly and Company by 1.8% during the fourth quarter. Abacus Planning Group Inc. now owns 2,409 shares of the company's stock valued at $1,860,000 after purchasing an additional 43 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock traded up $1.00 during midday trading on Friday, hitting $874.12. The stock had a trading volume of 3,937,537 shares, compared to its average volume of 3,765,032. Eli Lilly and Company has a 52-week low of $711.40 and a 52-week high of $972.53. The company has a market capitalization of $829.82 billion, a PE ratio of 74.65, a P/E/G ratio of 1.39 and a beta of 0.42. The firm's fifty day moving average is $799.63 and its two-hundred day moving average is $846.07. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 86.26% and a net margin of 23.51%. On average, research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company declared that its board has authorized a share repurchase program on Monday, December 9th that allows the company to repurchase $15.00 billion in shares. This repurchase authorization allows the company to reacquire up to 2% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company's leadership believes its stock is undervalued.

Eli Lilly and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 14th will be issued a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, February 14th. This is a boost from Eli Lilly and Company's previous quarterly dividend of $1.30. This represents a $6.00 dividend on an annualized basis and a yield of 0.69%. Eli Lilly and Company's dividend payout ratio (DPR) is currently 51.24%.

Analyst Ratings Changes

LLY has been the subject of several research analyst reports. Wolfe Research assumed coverage on Eli Lilly and Company in a report on Friday, November 15th. They issued an "outperform" rating and a $1,000.00 price objective for the company. Bank of America reiterated a "buy" rating and issued a $997.00 price target on shares of Eli Lilly and Company in a research note on Tuesday, December 10th. Deutsche Bank Aktiengesellschaft lowered their price objective on shares of Eli Lilly and Company from $1,025.00 to $1,015.00 and set a "buy" rating on the stock in a research report on Monday, November 4th. Citigroup cut their target price on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating for the company in a research report on Tuesday, January 28th. Finally, Barclays lowered their price target on Eli Lilly and Company from $1,025.00 to $975.00 and set an "overweight" rating on the stock in a report on Thursday, October 31st. Four analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $997.50.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.